Comprehensive genomic profile that interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumor cancers.
Identifies all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements.
Identify clinically relevant genomic alterations associated with targeted therapies
Quantify clinical markers associated with immunotherapy response
Foundation one Heme (hematology malignancies & sarcomas)
Comprehensive genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas.
Designed to provide physicians with clinically actionable information relevant for diagnosis, risk-stratification and prognosis to guide treatment options for patients based on the genomic profile of their cancer.
Assess routine cancer specimens for all genes that are currently known to be somatically altered in hematologic malignancies and sarcomas.
Simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes.
Also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.